Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II safety study of intravenous 131I-IPA in recurrent high-grade glioma
2021-006426-43Phase 2Completed
- Sponsor
- Kepler Universitätsklinikum
- Start
- Jan 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 131I-iodofalan in high-grade glioma (HGG) and brain cancer, sponsored by Kepler Universitätsklinikum. Primary endpoint: Safety and tolerability of intravenous 131I-IPA. Started Jan 2022; status: completed.
02
Drugs
131I-iodofalan
03
Conditions
high-grade glioma (HGG)brain cancer
Beyond the preview
Go deeper on 2021-006426-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006426-43.